Immuno-Oncology (IO) Market Size, Share, Growth, Analysis and Forecast to 2030

Immuno-Oncology (IO) Market Overview:

The global immuno-oncology market is projected to grow at a robust CAGR of approximately 21% over the next five years. This strong expansion is fueled by the rising global cancer burden, continuous breakthroughs in immunotherapy and precision medicine, supportive regulatory frameworks, increasing investments in cancer immunotherapy research and development, and the broadening use of immuno-oncology treatments beyond conventional cancer indications.

Download Sample PDF Copy: https://meditechinsights.com/immuno-oncology-market/request-sample/

Report Overview

Immuno-oncology represents one of the most transformative advances in modern cancer therapy, leveraging the body’s immune system to detect and destroy malignant cells. In contrast to traditional treatment modalities such as chemotherapy and radiation, which act directly on tumors, immuno-oncology therapies work by stimulating or restoring immune system function. Major therapeutic approaches include immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors, chimeric antigen receptor T-cell (CAR-T) therapies, bispecific antibodies, and therapeutic cancer vaccines. These innovations have significantly reshaped cancer treatment by delivering longer-lasting responses and improved survival across multiple cancer types. Current research efforts are centered on improving treatment effectiveness, addressing resistance mechanisms, and extending the applicability of immuno-oncology through combination regimens and personalized treatment strategies.

Rising Cancer Incidence to Drive Market Growth

The increasing incidence and prevalence of cancer worldwide remain key drivers of demand for immuno-oncology therapies. As cancer continues to rank among the leading causes of mortality globally, the need for more effective and durable treatment options is intensifying. According to the World Health Organization, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022. Cancer incidence is expected to rise sharply due to aging populations, changing lifestyles, and environmental exposures, with projections estimating more than 35 million new cases by 2050—representing a 77% increase from 2022 levels. The growing burden of lung, colorectal, breast, and prostate cancers has accelerated the adoption of innovative therapies such as immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Additionally, lifestyle-related risk factors including smoking, physical inactivity, and obesity further contribute to higher cancer rates, reinforcing the need for advanced immuno-oncology solutions. Consequently, pharmaceutical and biotechnology companies are significantly increasing investments in research to develop next-generation therapies that enhance clinical outcomes and extend patient survival.

Download Sample PDF Copy: https://meditechinsights.com/immuno-oncology-market/request-sample/

Advancements in Immuno-Oncology Therapies: Emerging Innovations and Opportunities

The immuno-oncology landscape is evolving rapidly, supported by recent regulatory approvals of bispecific T-cell engagers (BiTEs) and renewed momentum in cancer vaccine development, particularly mRNA-based platforms. Cell-based therapies, including CAR-T treatments, are expanding into additional cancer indications and earlier stages of therapy, such as non-Hodgkin’s lymphoma. Bispecific antibodies are gaining attention for their ability to redirect T cells while simultaneously modulating immune checkpoints, offering potential solutions to overcome immune exhaustion. Moreover, next-generation immune checkpoint inhibitors that target multiple pathways may provide improved efficacy compared to conventional combination therapies. Advances in targeting and reshaping the tumor microenvironment to address resistance mechanisms are creating substantial growth opportunities and driving innovation across the immuno-oncology market.

Competitive Landscape

The global immuno-oncology market features a competitive mix of well-established pharmaceutical companies and emerging biotechnology firms. Key players include Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., AstraZeneca, Sanofi, Moderna, Inc., GSK plc, AbbVie Inc., and Merck & Co., Inc., among others. Market participants are actively pursuing strategies such as novel product development, strategic alliances and collaborations, and expansion into new geographic regions to strengthen their market position and accelerate innovation.

Browse Report: https://meditechinsights.com/immuno-oncology-market/

Market Segmentation

This report by Medi-Tech Insights provides the size of the global immuno-oncology market at the regional- and country-level from 2023 to 2030. The report further segments the market based on therapy type, cancer type, end user.

• Market Size & Forecast (2023-2030), By Therapy Type, USD Million
  • Immune Checkpoint Inhibitors (ICIs)
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Bispecific Antibodies
  • Monoclonal Antibodies
  • Oncolytic Viruses
  • Cytokine Therapy
  • Others
• Market Size & Forecast (2023-2030), By Cancer Type, USD Million
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Others
• Market Size & Forecast (2023-2030), By End User, USD Million
  • Hospitals & Cancer Treatment Centers
  • Specialty Clinics
  • Others
• Market Size & Forecast (2023-2030), By Region, USD Million
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Related Report:

Proteomics Market - https://www.pharmiweb.com/press-release/2026-02-03/proteomics-market-2029-size-share-growth-analysis-and-research-report-to-forecast

Pharmacy Automation Market - https://www.pharmiweb.com/press-release/2026-02-03/pharmacy-automation-market-report-with-statistics-growth-opportunities-sales-trends-service-applications-and-forecast-2029

High Flow Oxygen Therapy Market - https://www.pharmiweb.com/press-release/2026-02-03/high-flow-oxygen-therapy-market-2026-revenue-advancement-strategy-and-geographical-performance-forecast-to-2029

Biometrics as a Service (BaaS) in Healthcare Market -             https://www.pharmiweb.com/press-release/2026-02-03/biometrics-as-a-service-baas-in-healthcare-market-to-witness-a-leap-by-leaching-cagr-of-approximately-20-by-the-end-of-2029

Computed Tomography Market - https://www.pharmiweb.com/press-release/2026-02-03/computed-tomography-market-size-share-future-growth-top-key-players-and-forecast-till-2029

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com